Gilead Sciences (GILD)
(Delayed Data from NSDQ)
$83.61 USD
+0.57 (0.69%)
Updated Sep 27, 2024 04:00 PM ET
After-Market: $83.61 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$83.61 USD
+0.57 (0.69%)
Updated Sep 27, 2024 04:00 PM ET
After-Market: $83.61 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth A Momentum A VGM
Zacks News
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
by Zacks Equity Research
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Why Gilead (GILD) Might Surprise This Earnings Season
by Zacks Equity Research
Gilead (GILD) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Incyte (INCY) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Incyte's (INCY) fourth-quarter 2022 earnings are likely to have gained from higher Jakafi sales and incremental sales from newly approved drugs.
Why Gilead (GILD) is Poised to Beat Earnings Estimates Again
by Zacks Equity Research
Gilead (GILD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Will Eylea and Dupixent Fuel Regeneron's (REGN) Q4 Earnings?
by Zacks Equity Research
Regeneron's (REGN) fourth-quarter earnings are likely to have gotten a boost from the solid performances of Eylea and Dupixent.
Should iShares Select Dividend ETF (DVY) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for DVY
Regeneron (REGN) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Regeneron (REGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Should Franklin U.S. Low Volatility High Dividend Index ETF (LVHD) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for LVHD
Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Gilead Sciences (GILD) closed the most recent trading day at $83.62, moving -0.54% from the previous trading session.
Gilead Sciences (GILD) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Gilead (GILD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Gilead Sciences (GILD) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Gilead Sciences (GILD) closed the most recent trading day at $84.02, moving +0.95% from the previous trading session.
Gilead (GILD) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Investors' focus is likely to be on Gilead's (GILD) HIV franchise performance and oncology sales when the company reports its fourth-quarter 2022 results.
GILD or GMAB: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
GILD vs. GMAB: Which Stock Is the Better Value Option?
Gilead (GILD) Gains 21% in a Year: Will the Trend Continue?
by Zacks Equity Research
Biotech giant Gilead (GILD) gains 21% in the past 12 months as its core HIV business maintains momentum despite volatility.
Should You Invest in the VanEck Biotech ETF (BBH)?
by Zacks Equity Research
Sector ETF report for BBH
Gilead Sciences (GILD) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Gilead Sciences (GILD) closed at $85.41 in the latest trading session, marking a -1% move from the prior day.
Should SPDR Russell 1000 Yield Focus ETF (ONEY) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for ONEY
Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for IBB
Is iShares Select Dividend ETF (DVY) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for DVY
Gilead Sciences (GILD) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Gilead Sciences (GILD) closed at $87.19, marking a +0.06% move from the previous day.
Should You Invest in the iShares Biotechnology ETF (IBB)?
by Zacks Equity Research
Sector ETF report for IBB
Is Franklin U.S. Low Volatility High Dividend Index ETF (LVHD) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for LVHD
Gilead Sciences (GILD) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Gilead Sciences (GILD) closed at $85.50 in the latest trading session, marking a +0.13% move from the prior day.
Gilead's (GILD) Application for Trodelvy Gets EMA Validation
by Zacks Equity Research
Gilead Sciences (GILD) gets EMA validation for its application for breast cancer drug Trodelvy in the European Union.
Gilead Sciences (GILD) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Gilead Sciences (GILD) closed at $85.26, marking a +0.82% move from the previous day.